engleski

In rats with superior mesenteric vein-occlusion pentadecapeptide BPC 157 counteracts portal and caval hypertension and aortal hypotension, and GI- lesions in relation with no-system involvement

We focused on the superior mesenteric vein occlusion and stable gastric pentadecapeptide BPC 157, and NO-system involvement with L-NAME and L- arginine application. Recently, we demonstrated that in rats with 15 min superior mesenteric vein (SMV) occlusion, stable pentadecapeptide BPC 157 medication shows rapid presentation (SMV venography bellow occlusion) of the bypassing pathway SMV-middle colic vein (MCV)-inferior mesenteric vein (IMV)- SMV-portal vein (PV) and consistently counteracts huge SMV, PV, and inferior caval vein (ICV) hypertension, mild aortic hypotension, peaked P waves and tachycardia, marked venous thrombosis, and oxidative stress (Gastroenterology, Vol. 156, Issue 6, S-707–S-708). Likewise, 15 min SMV occlusion produced marked lesions in the stomach, duodenum, jejunum, cecum and colon, which BPC 157 counteracts. Methods. Medication (/kg) (BPC 157 (10 μg, 10 ng), L-NAME (5 mg), and/or L-arginine (100 mg) or saline (5 ml) (controls)) was applied as an abdominal bath immediately after SMV occlusion. Results. At the end of the 15 min, rats with SMV occlusion exhibit huge SMV, PV, and ICV hypertension, mild aortic hypotension (controls, means±SD mmHg, 59±4 (PV), 30±4 (SMV), 43±4 (ICV), 80±3 (abdominal aorta)) which were markedly opposed (BPC 157 rats) (10 μg: 14±4 (PV), 5±2 (SMV), 8±4 (ICV), 117±3 (abdominal aorta)). There were venous hypertension (assessed in PV, SMV, ICV) L-NAME 39±4 (PV), 26±4 (SMV), 64±4 (ICV) ; L- arginine 82±4 (PV), 74±4 (SMV), 48±4 (ICV) ; and aortal hypotension (L-NAME 107±3 ; L-arginine 72±3). L-NAME and L-arginine oppose each other response while venous hypertension remains (L- NAME+L- arginine 69±4 (PV), 62±4 (SMV), 39±4 (ICV)) as well as aortal hypotension (L-NAME+L- arginine 68±3). BPC 157, given with NO-agents, L- NAME (BPC 157+L-NAME), L-arginine (BPC 157+L- arginine) or L-NAME and L-arginine (BPC 157+L- NAME+L-arginine) markedly opposed their effects on venous hypertension (BPC 157+L-NAME 17±4 (PV), 12±4 (SMV), 8±4 (ICV) BPC 157+L-arginine 38±4 (PV), 32±4 (SMV), 28±4 (ICV) BPC 157+L-NAME+L- arginine 24±4 (PV), 21±4 (SMV), 27±4 (ICV)) and aortal hypotension (BPC 157+L-NAME: 118±3 BPC 157+L-arginine 111±4 BPC 157+L-NAME+L-arginine 108±4). Given alone BPC 157 and L-arginine attenuated the stomach, duodenum, jejunum, cecum and colon lesions, L-NAME aggravated jejunal and colonic lesions. Given together (L-NAME+L- arginine) opposed each other response. BPC 157 given with NO-agent(s) maintained its original beneficial effect. In conclusion, these beneficial effects in rats with SMV-occlusion indicate that pentadecapeptide BPC 157 counteracts portal and caval hypertension and aortal hypoten- sion, and GI-lesions in relation with NO-system involvement.

BPC 157 ; superior mesenteric vein ; GI tract

nije evidentirano